Meta-Analysis
Copyright ©The Author(s) 2024.
World J Virol. Mar 25, 2024; 13(1): 91457
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.91457
Table 3 Baseline laboratory parameters and hospital course
Parameter of interest
Frequency (%)
Hematocrit, median 42.60 (IQR 15.15)
Total leucocyte count (per µL), median 5800 (IQR 5800)
Platelet count (per µL), median 25500 (IQR 28250)
AST (U/L), median 4625 (IQR 11902.5)
ALT (U/L), median 3100 (IQR 2607)
AST/ALT ratio, median 2.45 (IQR 1.75)
Alkaline phosphatase (IU/L), median 191 (IQR 117)
Total bilirubin (mg/dL), median 5.5 (IQR 5.63)
Direct bilirubin (mg/dL), median 2.55 (IQR 2.75)
INR, median 2.13 (IQR 1.79)
Albumin (g/L), median 2.85 (IQR 0.48)
Creatinine (mg/dL), median 1.63 (IQR 2.12)
MELD score, median 27.5 (IQR 5)
Days of ICU stay, median 6 (IQR 2)
Specific therapies
N-acetyl cysteine 6 (31.6)
Types of organ support
Vasopressors 8 (42.1)
Renal replacement therapy 6 (31.6)
Ventilation6 (31.6)
MARS1 (5.3)
Organ failure 14 (73.7)
Neurological10 (52.6)
Cardiac8 (42.1)
Renal7 (36.8)
Respiratory
Complications
Hepatic encephalopathy13 (68.4)
Bleedings3 (15.8)
DVT1 (5.3)
Liver transplantation2 (10.5)
Death1 (5.3)